Sanofi $SNY Shares Bought by Causeway Capital Management LLC

Causeway Capital Management LLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 16.6% in the third quarter, Holdings Channel reports. The institutional investor owned 979,317 shares of the company’s stock after purchasing an additional 139,678 shares during the period. Causeway Capital Management LLC’s holdings in Sanofi were worth $46,224,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Waterfront Wealth Inc. raised its position in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after acquiring an additional 214 shares in the last quarter. HighPoint Advisor Group LLC boosted its holdings in Sanofi by 2.3% in the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after purchasing an additional 226 shares in the last quarter. HM Payson & Co. increased its stake in Sanofi by 3.4% in the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock valued at $342,000 after purchasing an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. increased its stake in Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock valued at $252,000 after purchasing an additional 238 shares during the last quarter. Finally, CreativeOne Wealth LLC raised its holdings in Sanofi by 2.8% during the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after purchasing an additional 241 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 0.4%

SNY stock opened at $44.35 on Tuesday. The company has a fifty day moving average price of $47.23 and a 200 day moving average price of $48.40. Sanofi has a 12 month low of $43.34 and a 12 month high of $60.12. The company has a market cap of $108.17 billion, a price-to-earnings ratio of 12.32, a price-to-earnings-growth ratio of 1.15 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup initiated coverage on Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.